• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro.

作者信息

ElZayat Emad M, Hassan Nadeen M, Mahmoud Rehab, Ibrahim Essam, Hassan Nourhan

机构信息

Biotechnology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.

Faculty of Biotechnology, October University for Modern Sciences and Arts (MSA University, 6 October City, Egypt.

出版信息

Sci Rep. 2025 Sep 18;15(1):32596. doi: 10.1038/s41598-025-16803-x.

DOI:10.1038/s41598-025-16803-x
PMID:40968124
Abstract
摘要

相似文献

1
MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro.在体外实验中，MOF增强了索拉非尼作为一种抗癌药物对肝癌和结直肠癌的敏感性和选择性。
Sci Rep. 2025 Sep 18;15(1):32596. doi: 10.1038/s41598-025-16803-x.
2
Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.细菌代谢产物丁酸盐通过调节索拉非尼靶向 microRNAs 来抑制肝癌的耐药性。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5823-5839. doi: 10.1007/s00432-022-04544-7. Epub 2022 Dec 30.
3
Decitabine regulates the resistance of HCC to sorafenib through demethylation.地西他滨通过去甲基化调节肝癌对索拉非尼的耐药性。
Clin Epigenetics. 2025 Jul 7;17(1):120. doi: 10.1186/s13148-025-01925-w.
4
In vivo CRISPR screening identifies POU3F3 as a novel regulator of ferroptosis resistance in hepatocellular carcinoma via retinoic acid signaling.体内CRISPR筛选确定POU3F3是通过视黄酸信号通路调控肝癌铁死亡抗性的新型调节因子。
Cell Commun Signal. 2025 Jul 10;23(1):329. doi: 10.1186/s12964-025-02285-x.
5
Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.新型 STAT3 寡核苷酸化合物抑制肝癌生长并克服对索拉非尼的获得性耐药。
Acta Pharmacol Sin. 2024 Aug;45(8):1701-1714. doi: 10.1038/s41401-024-01261-4. Epub 2024 Apr 12.
6
PIMREG modulation of PI3K/Akt pathway enhances sorafenib resistance in Huh7 cells.PIMREG对PI3K/Akt通路的调节增强了Huh7细胞对索拉非尼的耐药性。
Arab J Gastroenterol. 2025 Aug;26(3):241-249. doi: 10.1016/j.ajg.2025.05.002. Epub 2025 Jun 28.
7
Integrated network pharmacology and experimental validation reveal EGFR/p53/Bcl-2-mediated anti-hepatocellular carcinoma effects of Zedoary Turmeric Oil.整合网络药理学与实验验证揭示莪术油通过EGFR/p53/Bcl-2介导的抗肝癌作用
J Ethnopharmacol. 2025 Jul 3;352:120241. doi: 10.1016/j.jep.2025.120241.
8
ESR1-dependent suppression of LCN2 transcription reverses autophagy-linked ferroptosis and enhances sorafenib sensitivity in hepatocellular carcinoma.雌激素受体1（ESR1）依赖性抑制脂质运载蛋白2（LCN2）转录可逆转自噬相关的铁死亡，并增强肝癌对索拉非尼的敏感性。
J Physiol Biochem. 2025 Mar 24. doi: 10.1007/s13105-025-01073-y.
9
DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K/AKT Pathway.DDX42通过调节GRB2 RNA成熟和激活PI3K/AKT通路增强肝癌细胞增殖、辐射抗性和索拉非尼抗性。
J Cell Mol Med. 2025 Aug;29(16):e70793. doi: 10.1111/jcmm.70793.
10
Sex-determining region Y-Box 4 promotes the progression of advanced hepatocellular carcinoma and enhances regulatory T-cell infiltration and immune suppression.性别决定区Y框蛋白4促进晚期肝细胞癌进展并增强调节性T细胞浸润及免疫抑制。
Cytojournal. 2025 Jun 2;22:56. doi: 10.25259/Cytojournal_27_2025. eCollection 2025.

本文引用的文献

1
Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives.用于癌症治疗的基于金属有机框架的智能刺激响应型药物递送系统：进展、挑战与未来展望
J Nanobiotechnology. 2025 Feb 28;23(1):157. doi: 10.1186/s12951-025-03252-x.
2
Research progress of sorafenib drug delivery system in the treatment of hepatocellular carcinoma: An update.索拉非尼药物传递系统治疗肝细胞癌的研究进展：更新。
Biomed Pharmacother. 2024 Aug;177:117118. doi: 10.1016/j.biopha.2024.117118. Epub 2024 Jul 14.
3
MOFs for next-generation cancer therapeutics through a biophysical approach-a review.
通过生物物理方法用于下一代癌症治疗的金属有机框架材料——综述
Front Bioeng Biotechnol. 2024 Jun 13;12:1397804. doi: 10.3389/fbioe.2024.1397804. eCollection 2024.
4
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
5
S-phase checkpoint prevents leading strand degradation from strand-associated nicks at stalled replication forks.S 期检查点防止停滞复制叉处链相关缺口导致的前导链降解。
Nucleic Acids Res. 2024 May 22;52(9):5121-5137. doi: 10.1093/nar/gkae192.
6
Recent advances in surface-mounted metal-organic framework thin film coatings for biomaterials and medical applications: a review.用于生物材料和医学应用的表面安装金属有机框架薄膜涂层的最新进展：综述
Biomater Res. 2023 Nov 10;27(1):115. doi: 10.1186/s40824-023-00454-y.
7
Multi-Bioinspired MOF Delivery Systems from Microfluidics for Tumor Multimodal Therapy.微流控技术制备多仿生 MOF 递药系统用于肿瘤多模式治疗
Adv Sci (Weinh). 2023 Nov;10(33):e2303818. doi: 10.1002/advs.202303818. Epub 2023 Oct 18.
8
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.癌症化疗及其他：当前状况、候选药物、相关风险以及靶向治疗的进展。
Genes Dis. 2022 Mar 18;10(4):1367-1401. doi: 10.1016/j.gendis.2022.02.007. eCollection 2023 Jul.
9
Exploring the pathogenesis of colorectal carcinoma complicated with hepatocellular carcinoma via microarray data analysis.通过微阵列数据分析探索结直肠癌合并肝细胞癌的发病机制。
Front Pharmacol. 2023 Jun 13;14:1201401. doi: 10.3389/fphar.2023.1201401. eCollection 2023.
10
Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges.克服癌症多药耐药性（MDR）：原因、机制、纳米治疗解决方案及挑战
Biomed Pharmacother. 2023 Jun;162:114643. doi: 10.1016/j.biopha.2023.114643. Epub 2023 Apr 7.